资源描述：
《ETV治疗96周后血清HBeAg、HBsAg定量与HBV DNA变化的相关性.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、ETV治疗96周后血清HBeAg、HBsAg定量与HBVDNA变化的相关性【摘要】目的临床观察恩替卡韦治疗HBeAg阳性慢性乙型肝炎96周后乙肝病毒血清标志物含量与HBVDNA含量的关系。方法收集20□年3月至2014年9月期间就诊于本院的HBeA呂阳性慢性乙型肝炎患者58例，给予恩替卡韦0.5mg口服，每口1次，随访96周。结果经过96周恩替卡韦治疗后ALT复常率77.59%,HBV-DNA转阴率72.4%,HBeAg转阴率39.65%,HBeAg血清转换率27.59%。治疗过程中HBeAg、HBV-DNA
2、定量值均呈下降趋势，随着治疗时间的延长，HBeAg、HBVDNA定量值持续下降，两者之间存在显著的正相关性，且具有统计学意义(R=0.801,P<0.05)；但HBsAg定量与血清HBeAg.HBVDNA变化水平之间无显著关系(P>0.05)。结论恩替卡韦有明显抑制血清HBVDNA复制和提高HBeAg血清学转换,HBeAg基线水平可以预测ETV治疗HBeAg阳性慢乙肝患者的HBeAg血清学转换率oHBeAg含量变化与HBVDNA含量变化存在显著的正相关性，HBsAg含量变化与HBVDNA含量变化无
3、明显相关性。【关键词】恩替卡韦；乙型，肝炎；肝炎e抗原TherelationofserumHBeAg、HBsAgcontentandHBVDNAloadchangebyentecavirtherapyafter48weeks【Abstract】ObjectiveToinvestigatetherelationofserumHBVmarkerscontentandHBV-DNAloadchangeinHBeAgPositivechronichepatitisBbyentecavirtreatafter48wee
4、ks.MethodsCollect!ng58casesofHBeAgPositivechronichepatitisBPatientsinourhospiitalfromMarch2011toJune2013.Everonereceivedtheentecavir(0.5mg/d)orally^ndthedurationoftherapywas48weeks.ResultsAfter48weeksoftreatment,therecoveryrateofALTwas77.59%,thenegativeconv
5、erstionrateofHBVDNAwas72.4%,thenegativeconverstionrateofHBeAgwas39.65%,andtheseroconversionrateofHBeAgwas27.59%.TreatmentprocessofHBeAgandHBVDNAcontentweresignificantlydecreased.Whentheextensionoftreatmenttime,HBeAgandHBVDNAcontentcontinuetodecline.Meanwhie
6、,wefoundthatthecontentofHBeAgwaspositivelycorrelatedwiththecontentofHBVDNA,thecorrelationwassatiisticallysignificant(R=0.801,P<0.05);ButtherewasnosignificantcorrelationbetweenHBsAgandHBeA呂、HBVDNAcontent(P>0.05)・ConclusionEntecavirhasobviouslyinhibited
7、HBVDNAreplicationandimprovedHBeAgseroconversion.ThebaselineofHBeAgcontentcouldpredicttherateofHBeAgseroconversioninHBeAgpositivechronichepatitisBpatients.HBeAgandHBVDNAcontentchangeshavesignificantpositivecorrelation,butHBsAgandHBVDNAcontentchangeshavenosig
8、nificantcorrelation.[Keywords]Entecavir；HepatitisB；HBeAg引言慢性乙型肝炎治疗的总体目标是：最大限度地长期抑制HBV,减轻肝细胞炎症坏死及肝纤维化，延缓和减少肝脏失代偿、肝硬化、HCC及其并发症的发生，从而改善生活质量和延长存活时间［2］。抗病毒治疗是关键,只要有适应证，且条件允许，就应进行规范的抗病毒治疗。恩替卡韦具有抑制HBV活性强、作用迅速
